NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,488

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-05	12.11 $	+2.98%	2,254,906
25-12-04	11.76 $	-0.42%	1,787,474
25-12-03	11.81 $	+8.15%	2,330,116
25-12-02	10.92 $	-6.51%	2,885,028
25-12-01	11.68 $	-8.82%	3,122,631

Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.11USD

Average target price

24.93USD

Spread / Average Target

+105.85%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
12.11 ^USD	+2.98%		-5.46%	-59.36%

Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE

Capitalization	1.36B 1.17B 1.09B 1.02B 1.88B 122B 2.04B 12.77B 4.93B 57.64B 5.09B 4.98B 211B	P/E ratio 2025 *	-8.76x	P/E ratio 2026 *	-8.17x
Enterprise value	1.36B 1.17B 1.09B 1.02B 1.88B 122B 2.04B 12.77B 4.93B 57.64B 5.09B 4.98B 211B	EV / Sales 2025 *	2.08x	EV / Sales 2026 *	1.97x
Free-Float	90.74%	Yield 2025 *	-	Yield 2026 *	-

Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE
Dec. 01	NovoCure Names Frank Leonard as Chief Executive	MT
Nov. 04	NovoCure Limited, Q3 2025 Earnings Call, Oct 30, 2025
Oct. 30	NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 30	NovoCure Q3 Net Loss Widens, Revenue Rises	MT
Oct. 30	Novocure Q3 revenue beats estimates	RE
Oct. 30	Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M	MT
Oct. 01	Novocure to report third quarter 2025 financial results	RE
Sep. 29	Novocure to present final results from pivotal phase 3 Metis trial of its Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer at 2025 Astro Annual Meeting	RE
Sep. 29	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of Its Tumor Treating Fields Therapy for Brain Metastases from Non-Small Cell Lung Cancer At 2025 ASTRO Annual Meeting	CI
Sep. 15	Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer	CI
Sep. 15	NovoCure's Optune Lua Receives Approval in Japan to Treat Certain Non-Small Cell Lung Cancer Patients	MT

Jul. 25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
Jul. 25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
Jul. 24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
Jul. 08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT

NovoCure Limited Stock

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Valuation: NovoCure Limited

Chart: NovoCure Limited

Latest news: NovoCure Limited

Last Transcript: NovoCure Limited

Analysts' recommendations: NovoCure Limited

Press Releases: NovoCure Limited

News in other languages: NovoCure Limited

Quotes and Performance

Course Extremes

Managers and Directors: NovoCure Limited

ETFs: NovoCure Limited

Medical Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Dec. 01	Novocure Appoints Company President Frank Leonard as Chief Executive Officer	BU
Nov. 26	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference	BU
Nov. 12	Novocure to Participate in 2025 Jefferies Global Healthcare Conference	BU
Oct. 30	NovoCure: Q3 Earnings Snapshot	AQ
Oct. 30	Novocure Reports Third Quarter 2025 Financial Results	BU

Jul. 03	Novocure presenterà i dati finali dell’endpoint secondario dal trial di fase 3 PANOVA-3 sui Tumor Treating Fields (TTFields) nel carcinoma pancreatico al Congresso ESMO GI 2025
Apr. 28	Optune Lua® de Novocure obtiene aprobación con el marcado CE para el tratamiento de cáncer de pulmón no microcítico metastásico
Apr. 28	Optune Lua® de Novocure reçoit l'approbation du marquage CE pour le traitement du cancer du poumon non à petites cellules métastatique
Apr. 28	Optune Lua® di Novocure riceve l'approvazione del marchio CE per il trattamento del carcinoma polmonare non a piccole cellule (NSCLC) metastatico
Apr. 23	Optune Lua® von Novocure erhält CE-Kennzeichnung für die Behandlung von metastasierendem nicht-kleinzelligem Lungenkrebs (mNSCLC)

1 day	+2.98%
1 week	-5.46%
Current month	-5.46%
1 month	+4.31%
3 months	-1.38%
6 months	-26.38%
Current year	-59.36%

1 week	10.79	12.58
1 month	10.7	12.89
Current year	10.7	31.17
1 year	10.7	34.13
3 years	10.7	120.03
5 years	10.7	232.76
10 years	5.95	232.76

Manager	Title	Age	Since
Frank Leonard CEO	Chief Executive Officer	45	2025-11-30
Christoph Brackmann DFI	Director of Finance/CFO	51	2024-12-31
Nicolas Leupin CTO	Chief Tech/Sci/R&D Officer	51	2024-01-03

Director	Title	Age	Since
Asaf Danziger BRD	Director/Board Member	58	2011-12-31
Bill Doyle CHM	Chairman	62	2008-12-31
Kin Yip Leung BRD	Director/Board Member	64	2011-08-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NOVOCURE LIMITED	+2.98%	-5.46%	-54.47%	-84.47%	1.36B
SHOCKWAVE MEDICAL	-0.01%	+0.01%	+0.01%	+37.71%	12.57B
PENUMBRA, INC.	+2.02%	+2.55%	+23.88%	+41.82%	11.77B
MASIMO CORPORATION	-0.41%	-0.53%	-16.36%	-0.61%	7.61B
GETINGE AB	+0.24%	-1.72%	+24.93%	-16.39%	6.11B
ASAHI INTECC CO., LTD.	-0.03%	+4.60%	+14.22%	+22.64%	5.23B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-0.14%	+1.23%	+7.24%	+0.61%	5.1B
APT MEDICAL INC.	-0.17%	+3.12%	-7.29%	+75.93%	4.82B
INARI MEDICAL, INC.	+0.05%	-.--%	+55.10%	+12.46%	4.7B
CHEMOMETEC A/S	-1.00%	-5.18%	+52.99%	-16.68%	2.01B
Average	+0.35%	-0.61%	+10.03%	+7.30%	6.13B
Weighted average by Cap.	+0.37%	+0.33%	+11.05%	+20.55%

	2025 *	2026 *
Net sales	651M 560M 524M 489M 903M 58.61B 982M 6.13B 2.37B 27.68B 2.44B 2.39B 101B	688M 591M 554M 516M 953M 61.9B 1.04B 6.48B 2.5B 29.23B 2.58B 2.53B 107B
Net income	-155M -133M -125M -116M -215M -13.96B -234M -1.46B -564M -6.59B -582M -570M -24.11B	-172M -148M -139M -129M -239M -15.49B -259M -1.62B -626M -7.31B -646M -632M -26.74B
Net Debt	-	-